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Abstract Sepsis, also known as systemic inflammatory
response syndrome, is a life-threatening condition caused
by a pathogenic agent and leading to multiple organ dys-
function syndrome. One of the factors responsible for the
excessive intensification of the inflammatory response in
the course of inflammation is high-mobility group protein
B1 (HMGB1). HMG-1 is a nuclear protein which, after
being released to the intercellular space, has a highly pro-
inflammatory effect and acts as a late mediator of lethal
damage. The purpose of this study was to examine whether
the anti-inflammatory action of riboflavin is accompanied
by inhibition of HMGB1 release during peritoneal
inflammation and zymosan stimulation of macrophages.
Peritonitis was induced in male BALB/c and C57BL/6J
mice via intraperitoneal injection of zymosan (40 mg/kg).
RAW 264.7 macrophages were activated with zymosan
(250 lg/ml). Riboflavin (mice, 50 mg/kg; RAW 264.7,
25 lg/ml) was administered 30 min before zymosan,
simultaneously with, or 2, 4, 6 h after zymosan. Addi-
tionally, mRNA expression of HMGB1 and its intracellular
and serum levels were evaluated. The research showed that
riboflavin significantly reduces both the expression and the
release of HMGB1; however, the effect of riboflavin was
time-dependent. The greatest efficacy was found when
riboflavin was given 30 min prior to zymosan, and also 2
and 4 h (C57BL/6J; RAW 264.7) or 4 and 6 h (BALB/c)
after zymosan. Research showed that riboflavin influences
the level of HMGB1 released in the course of inflamma-
tion; however, further study is necessary to determine its
mechanisms of action.
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Introduction
High-mobility group protein B1 (HMGB1) is a member of
the HMG protein family that is common in the nucleus of
quiescent cells. Its basic function is connected with DNA
binding and nucleosome stabilization, as well as with the
regulation of the gene transcription and expression process.
Nevertheless, recent studies reported that in certain situa-
tions HMGB1 may be released from cells to the
intercellular space and, acting via various receptors such as
RAGE, TLR2, TLR4 or TLR9, induces a pro-inflammatory
activation of neutrophils or macrophages (Huang et al.
2010; Kim et al. 2013). HMGB1 release may occur as a
passive leakage from necrotic cells or as an active process
therefore of a pro-inflammatory activation of macrophages
with endotoxins or pro-inflammatory cytokines (Andersson
and Tracey 2011; Youn et al. 2011). Initially, in the active
process HMGB1 is transported to cytoplasm, while release
from the cell requires its acetylation, phosphorylation or
methylation (Huang et al. 2010). HMGB1 is described as a
late mediator of lethal systemic inflammation, because its
level in serum increases after the principle peak of early
pro-inflammatory cytokines, reaching its maximum at
about 18–24 h or later. The consequence of HMGB1
influence upon immunocompetent cells is the stimulation
of releasing inflammatory agents which results in
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amplification of the immunological response, due to which
acute tissue damage occurs (Huang et al. 2010; Wang et al.
1999; Wu et al. 2012). Both sepsis and severe endotoxemia
conditions may result in the development of multiple organ
dysfunction syndrome (MODS) which occurs as a conse-
quence of the excessive and protracted activation of the
immune system (e.g. HMGB1 release). Research shows
that the model of zymosan-induced peritonitis, described as
the condition of systemic inflammation, is optimum to test
MODS, because mechanisms generated thereby best
demonstrate changes in the human body (Volman et al.
2005). We previously showed an anti-inflammatory activ-
ity of riboflavin in the model of zymosan-induced
peritonitis (Mazur-Bialy et al. 2011, 2012). The purpose of
this study was to evaluate the effect of riboflavin admin-
istration on HMGB1 gene expression and protein release
from cells. The study was conducted in the course of
zymosan-induced peritonitis in C57BL/6J and BALB/c
mice as well as on zymosan-stimulated macrophages RAW
264.7. Protective effect of riboflavin administration was
mentioned before (Al-Harbi et al. 2014; Bütün et al. 2015;
Cheung et al. 2014; Mal et al. 2013; Mazur-Bialy et al.
2011; Shih et al. 2010; Toyosawa et al. 2004). Previous
studies had shown that riboflavin reduces the inflammatory
response in the course of severe endotoxemia, inhibits the
release of pro-inflammatory cytokines (Mal et al. 2013;
Mazur-Bialy et al. 2011, 2012; Toyosawa et al. 2004) and
decreases the mortality rate of animals in septic shock
(Shih et al. 2010; Toyosawa et al. 2004) as well as reduces
the hepatocellular injury and hepatotoxicity (Al-Harbi et al.
2014; Sanches et al. 2014). Therefore, determining whether
the observed anti-inflammatory activity of riboflavin is
connected with HMGB1 release seems to be important.
Materials and Methods
Animals
The study was conducted on 6-week-old male mice of
C57BL/6J and BALB/c strains purchased from a licensed
animal colony (Slaboszow, Poland). The animals were kept
in standard conditions: temperature 20 ± 2 C, 12:12 LD,
with free access to water and food. All procedures
involving the animals were approved by the Local Com-
mittee on Animal Care at the Jagiellonian University
(License No. 77/2011).
Experimental Peritonitis
After 1 week of acclimatization, the animals were divided
into experimental groups on a random basis (four animals
per group). Peritonitis was induced by an intraperitoneal
(i.p.) injection of zymosan A (Z, 40 mg/kg; Sigma-Aldrich,
St. Louis, MO, USA). Some animals received a riboflavin
i.p. injection (50 mg/kg; Sigma-Aldrich, St. Louis, MO,
USA) for 30 min either before zymosan, with zymosan or
2, 4, 6 h after i.p. zymosan injection. Control animals
received only sterile 0.9 % phosphate buffered saline
(PBS; Polfa Kutno, Poland). Zymosan and riboflavin were
prepared freshly in sterile PBS. At selected time points of
inflammation (0, 2, 6, 24, 30 h), the mice were killed by
decapitation. The peritoneal fluid and blood were retrieved.
Cell pellets, fluids and serum were stored at -20 C until
further analysis.
Cell Culture
Macrophage cell line RAW 264.7, free of mycoplasma,
was obtained from the European Culture Collection
(Sigma-Aldrich, St. Louis, MO, USA). The cells were
cultured in DMEM medium (Sigma-Aldrich, St. Louis,
MO, USA) supplemented with antibiotics and 10 % fetal
bovine serum (Sigma-Aldrich, St. Louis, MO, USA). For
the experiments, cells were cultured with or without ribo-
flavin (25 lg/ml) administered 30 min before zymosan
(250 lg/ml), with zymosan or 2, 4, 6 h after zymosan
stimulation. The cell pellets and supernatants were col-
lected at selected time points during the experiments (0, 18,
24, 30 h) and were stored store at -20 C until further
analysis.
HMGB1 Expression
Total RNA from RAW 264.7 cells and mice peritoneal
leukocytes were isolated using an RNeasy Plus Mini Kit
(Qiagen, Hilden, Germany; No. 74134) at hour 24 of the
experiment. RNA was reverse transcribed using a High
Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster
City, CA, USA; No. 4387406). Real-time PCR was carried
out in a StepOne Plus system (Applied Biosystems, Foster
City, CA, USA) using TaqMan Gene Expression Master
Mix and TaqMan Gene Expression Assays (Applied
Biosystems, Foster City, CA, USA) for HMGB1 (Assay
ID: Mm00849805_gH). PCR amplification was performed
under the following conditions: 95 C denaturation for
10 min, followed by 40 cycles of 95 C for 15 s, then
primer hybridization and extension at 60 C for 1 min.
Glyceraldehyde phosphate dehydrogenase (GAPDH) was
used as a reference gene (Applied Biosystems, Foster City,
CA, USA; Assay ID: Mm99999915_g1). Four independent
replications for each riboflavin concentration were per-
formed. The relative transcript expression was calculated
using the 2DDCt method as described by Livak and Sch-
mittgen (2001).




To assess the level of HMGB1 released by both zymosan-
stimulated RAW 264.7 macrophages as well as mice
peritoneal leukocytes, a commercial ELISA kit was used
(IBL International, Hamburg, Germany). The HMGB1
level was tested in previously frozen cell culture super-
natant and mice serum collected at hour 30 of the
experiment. The analysis was performed according to the
manufacturer’s instructions. Moreover, for evaluation of
the intracellular (cytoplasmic and nuclear) HMGB1 con-
tent, RAW 264.7 cells were harvested 18 h after
stimulation, washed twice in PBS and then the cytoplasmic
and nuclear protein was isolated using a commercial Cell
Extraction kit (Applied Biosystem; Foster City, CA, USA),
according to the manufacturer’s procedure. Before analy-
sis, samples of both cytoplasmic and nuclear proteins were
normalized for protein concentrations. The levels of
HMGB1 were assessed as described above.
Quantification of TNF-a and IL-6 Levels
The cytokine levels were measured in the supernatant or
peritoneal fluid collected in the second (tumor necrosis
factor (TNF)-a) or sixth hour (interleukin (IL)-6) after
zymosan administration in samples frozen prior to analysis
at -20 C. The analyses were performed using the com-
mercial ELISA Kit (Diaclone, France; for both) according
to the instructions provided by the producer.
Statistical Analysis
Data were analyzed by the Dunkan’s new multiple range
test 3.1. The level of statistical significance was set at 0.05.
All data were expressed as mean ± standard deviation
(X ± SD).
Results and Discussion
High-mobility group protein B1 is a protein involved in
many biological processes. Apart from its role as a nucleus
factor, it also contributes in the immune response or
pathomechanism of various immune-mediated diseases
such as sepsis or rheumatoid arthritis (Huang et al. 2010).
This study shows that peritoneal administration of
zymosan induces HMGB1 release, which is responsible for
significant increase in its serum level in the 30th hour of
inflammation. Moreover, an interstrain difference in the
quantity of released HMGB1 may also be observed.
C57BL/6J mice with predominant Th1-response presented
HMGB1 levels nearly 51 % higher than BALB/c mice with
predominant Th2-response. As reported by Messmer et al.
(2004), HMGB1 induced the Th1 polarization of the
immune response that dominates in C57BL/6J mice. It can
be argued that this phenomenon may have a relationship
with an interstrain difference at the level of maximal
HMGB1 release observed between C57BL/6J and BALB/c
mice. As expected, administration of riboflavin reduced the
level of released HMGB1. The greatest efficacy for the
inhibition of HMGB1 release was observed in the case of
riboflavin supplementation 30 min before zymosan, where
in two strains this level was reduced by 24 % or 61 % in
BALB/c mice (Fig. 1a) or C57BL/6J mice (Fig. 1b),
respectively, and by 39 % in RAW 264.7 macrophages
(Fig. 1c). Simultaneous administration of zymosan and
riboflavin significantly reduced HMGB1 levels only in
BALC/c mice (21 %; Fig. 1b), while administrating ribo-
flavin 2, 4 or 6 h after the stimulation reduced HMGB1
levels in BALB mice by 21 and 15 % (in the fourth and
sixth hour, respectively; Fig. 1b), in C57BL mice by 47
and 34 % (in the second and fourth hour, respectively;
Fig. 1b), and in RAW 264.7 macrophages by 38 and 21 %
(in the second and fourth hour, respectively; Fig. 1c).
HMGB1 release into the extracellular environment
proceeds through either passive or active transport. In
passive transport, HMGB1 is released by cells with dam-
aged membrane integrity, as can be observed in the case of
necrotic or late apoptotic cells undergoing second necrosis.
In such cases, HMGB1 conveys the signal of cell damage
to the neighboring structures intensifying inflammatory
processes and activating innate and adaptive immune
responses (Andersson and Tracey 2011; Huang et al. 2010).
Research shows, however, that apoptotic cells keep
HMGB1 bound with DNA and do not release it into the
extracellular space (Scaffidi et al. 2002). Nevertheless, the
excessive accumulation of apoptotic cells in the inflam-
matory area stimulates macrophages to HMGB1 release
(Qin et al. 2006). We did not demonstrate any impact of
riboflavin on the intensification of apoptosis and necrosis in
the course of peritonitis. Therefore, riboflavin-modulated
changes in the level of released HMGB1 are likely to be a
result of an active rather than a passive mechanism (data
not shown). After activation by an inflammatory agent,
HMGB1 is initially translocated from the nucleus to the
cell cytoplasm where its level increases up to the 18th hour
and is maintained up to 36 h. HMGB1 active release
requires its acetylation, phosphorylation or methylation.
Only at the 18th hour does the mRNA expression level for
HMGB1 increase in the cell nucleus and this is maintained
for up to 48 h. Re-formed HMGB1 may then be released
into the intercellular space where it intensifies the activa-
tion of immunocompetent cells (Wu et al. 2012). In the
present study the level of mRNA expression for HMGB1
genes were assessed both in cells isolated from the
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inflammatory area and in RAW 264.7 macrophages;
moreover, intracellular HMGB1 content was measured in
RAW 264.7 cell lysates.
Both in peritoneal leukocytes and RAW 264.7 cells, the
administration of zymosan induced an elevation in
HMGB1 mRNA expression (Fig. 1, right panel). More-
over, our data demonstrated the significant reduction of
HMGB1 expression in all groups upon administration of
riboflavin 30 min prior to zymosan and in the second and
fourth hour of inflammation in C57BL mice (41, 27 and
23 %, respectively; Fig. 1b) and RAW 264.7 cells (33, 37
and 21 %, respectively; Fig. 1c), and additionally, in the
sixth hour in BALB mice (27, 35, 31 and 21 %, respec-
tively; Fig. 1a). The analysis of cytoplasmic and nuclear
level of HMGB1 at the 18th hour of stimulation, allowing
for indirect evaluation of its translocation from the nucleus
to the cytoplasm, showed no difference between the study
groups. This result may suggest that a reduction in the
serum or supernatant HMGB1 level observed after ribo-
flavin administration is not the outcome of blocking its
transportation to the cytoplasm. However, it has to be
remembered that, in these early hours the mRNA expres-
sion is initiated and the whole HMGB1 accumulated in the
cell where it is a constitutive component of the nucleus. It
seems, therefore, that changes in HMGB1 level observed
after riboflavin treatment may be due to reduction in its
subsequent expression at the mRNA level or impaired
maturation of HMGB1 in the cytoplasm—as described
earlier in the text by pointing to the need of its acetylation,
phosphorylation or methylation prior to the process of
active release from the cell.
It should also be mentioned that HMGB1 release occurs
as a result of stimulating cells with both the endotoxin and
pro-inflammatory cytokines (Huang et al. 2010; Wang
et al. 1999). Assessment of TNF-a and IL-6 levels in
C57BL mice and RAW 264.7 macrophages in the second
and sixth hour of the inflammatory process demonstrated a
significantly lower level of both TNF-a (Fig. 2, left panel)
and IL-6 (Fig. 2, right panel) upon riboflavin administra-
tion 30 min prior to zymosan; and also that of IL-6 in
groups supplemented with riboflavin 2 and 4 h after
zymosan. The level of TNF-a was reduced by 37 and
29 %, respectively, in C57BL/6J mice and RAW 264.7
macrophages, while IL-6 was reduced in C57BL/6J and
RAW 264.7 by more than 35 % at all tested time points.
This observation may suggest that administration of ribo-
flavin has an anti-inflammatory effect, reducing the level of
































































































Fig. 1 Influence of riboflavin
on HMGB1 release (left panel)
in the 30th hour and expression
of HMGB1 mRNA (right panel)
in the 24th hour of inflammatory
process induced by i.p.
administration of zymosan
(40 mg/kg) at BALB/c (a) and
C57BL/6J mice (b) and by
RAW 264.7 macrophages
(c) stimulated with zymosan
(250 lg/ml). The inflammation
was modulated by riboflavin
supplementation (50 mg/kg for
mice or 25 lg/ml for RAW
264.7 macrophages) 30 min
prior to zymosan,
simultaneously with zymosan or
2, 4, 6 h after zymosan. The
results are presented as mean
values with a standard
deviation. N = 4; p\ 0.05.
Statistically significant
differences determined relative
to control values are marked
with the following symbols over
the bars: *p\ 0.05; **p\ 0.01
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of BALB mice, no effect of riboflavin administration on
TNF-a and IL-6 release was observed, which is in agree-
ment with our previous findings. Considering the above
mentioned results, it may be assumed that the inhibition of
HMGB1 release may be followed by at least two mecha-
nisms. In case of C57BL/6J and RAW 264.7 macrophages,
HMGB1 inhibition was associated with reduction of pro-
inflammatory cytokines, which was not observed in BALB/
c mice in which HMGB1 inhibition was found. Therefore,
there is a need to search for another mechanism of HMGB1
inhibition.
In conclusion, numerous studies showed that riboflavin
has both analgesic and anti-inflammatory effects, reducing
the mortality rate from septic shock. This study demon-
strated for the first time that administration of riboflavin in
both zymosan-induced peritonitis and in vitro macrophages
model reduced the release of HMGB1—the key agent
responsible for multiple organ dysfunctions and lethality in
the case of sepsis or severe endotoxemia. However, future
studies are needed to determine whether or not the appli-
cation of riboflavin in other inflammatory models will also
result in the impairment of HMGB1 release. Also, it has to
be verified if inhibition of the HMGB1 release occurs
either as a direct effect of riboflavin administration or as a
secondary effect resulted from the inhibition of the key
inflammatory cytokine after riboflavin treatment.
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